| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $75M |
Buys | $5,685,126 | 7 | 100 |
Sells | $0 | 0 | 0 |
| BROADWOOD PARTNERS, L.P. | 10 percent owner | 7 | $5.69M | 0 | $0 | $5.69M |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Over the last 12 months, insiders at Insight Molecular Diagnostics Inc. have bought $5.69M and sold $0 worth of Insight Molecular Diagnostics Inc. stock.
On average, over the past 5 years, insiders at Insight Molecular Diagnostics Inc. have bought $12.79M and sold $125,061 worth of stock each year.
Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. (10 percent owner) — $5.69M.
The last purchase of 250,923 shares for transaction amount of $913,134 was made by BROADWOOD PARTNERS, L.P. (10 percent owner) on 2026‑04‑27.
$9,405,928 | 107 | 12.61% | $152.31M | |
$22,693,451 | 105 | 8.15% | $146.8M | |
Insight Molecular Diagnostics Inc. (IMDX) | $66,137,559 | 49 | 6.29% | $136.89M |
$18,994,888 | 46 | 88.59% | $115.54M | |
$140,595,157 | 34 | 17.93% | $144.5M | |
$109,415,500 | 33 | 18.13% | $144.42M | |
$38,601,028 | 29 | 1.18% | $118.1M | |
$226,127 | 22 | -27.62% | $127.19M | |
$161,692,548 | 20 | 18.00% | $159.86M | |
$4,701,608 | 14 | -4.34% | $155.5M | |
$156,530,514 | 13 | 45.71% | $110.08M | |
$515,321 | 12 | -2.55% | $127.8M | |
$9,999,920 | 10 | -40.03% | $111.48M | |
$1,073,250 | 10 | 19.46% | $120M | |
$13,919,584 | 9 | -30.43% | $147.73M | |
$2,762,881 | 8 | -10.76% | $134.91M | |
$22,090,972 | 7 | -3.49% | $141.26M | |
$99,355,998 | 7 | -65.74% | $150.83M | |
$43,340,011 | 7 | 45.36% | $123.03M |
| Increased Positions | 17 | +58.62% | 438,416 | +2.69% |
| Decreased Positions | 9 | -31.03% | 86,190 | -0.53% |
| New Positions | 9 | New | 283,676 | New |
| Sold Out Positions | 2 | Sold Out | 16,503 | Sold Out |
| Total Postitions | 37 | +27.59% | 17M | +2.16% |